Cancer
|
OPPORTUNITY NUMBER |
OPPORTUNITY TITLE |
AGENCY NAME |
POSTED DATE |
CLOSE DATE |
| RFA-HS-22-001 | Reducing Racial and Ethnic Healthcare Disparities in Chronic Conditions by Dissemination and Implementation of Patient Centered Outcomes Research (PCOR) Evidence (R18) | HHS-AHRQ | 05/26/2022 | 06/17/2022 |
| PAR-22-187 | NCI Research Specialist (Laboratory-based Scientist) Award (R50 Clinical Trial Not Allowed) | HHS-NIH11 | 05/25/2022 | 11/02/2022 |
| PAR-22-188 | NCI Research Specialist (Core-based Scientist) Award (R50 Clinical Trial Not Allowed) | HHS-NIH11 | 05/25/2022 | 11/02/2022 |
| RFA-CA-22-027 | Research to Understand and Address the Survivorship Needs of Individuals Living with Advanced Cancer (R01 Clinical Trial Optional) | HHS-NIH11 | 05/12/2022 | 09/29/2023 |
| PAR-22-131 | Imaging, Biomarkers and Digital Pathomics for the Early Detection of Premetastatic Cancer and Precancerous Lesions Associated with Lethal Phenotypes (R01 Clinical Trial Optional) | HHS-NIH11 | 04/12/2022 | 09/07/2025 |
| PAR-22-136 | Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional) | HHS-NIH11 | 04/11/2022 | 06/17/2024 |
| RFA-CA-22-021 | Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) | HHS-NIH11 | 03/24/2022 | 11/17/2022 |
| PAR-22-140 | Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 03/18/2022 | 05/07/2025 |
| PAR-22-139 | Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 03/18/2022 | 05/07/2025 |
| PAR-22-114 | Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional) | HHS-NIH11 | 02/25/2022 | 01/23/2025 |
| PAR-22-086 | Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 02/18/2022 | 05/07/2025 |
| PAR-22-085 | Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 02/18/2022 | 05/07/2025 |
| PAR-22-084 | Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 01/21/2022 | 05/07/2025 |
| PAR-22-099 | Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional) | HHS-NIH11 | 01/21/2022 | 05/07/2025 |
| PAR-22-083 | Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 01/21/2022 | 05/07/2025 |
| RFA-CA-22-008 | Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional) | HHS-NIH11 | 01/03/2022 | 09/22/2022 |
| RFA-CA-22-005 | Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) | HHS-NIH11 | 01/03/2022 | 09/22/2022 |
| RFA-CA-22-008 | Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P01 Clinical Trial Optional) | HHS-NIH11 | 01/03/2022 | 09/22/2022 |
| RFA-CA-22-009 | Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional) | HHS-NIH11 | 01/03/2022 | 09/22/2022 |
| RFA-CA-22-002 | Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | HHS-NIH11 | 11/23/2021 | 09/22/2022 |
| RFA-CA-22-001 | Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | HHS-NIH11 | 11/23/2021 | 09/22/2022 |
| PAR-22-071 | Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 11/23/2021 | 11/17/2024 |
| RFA-RM-22-006 | Expert-Driven Small Projects to Strengthen Gabriella Miller Kids First Discovery (R03 Clinical Trial Not Allowed) | HHS-NIH11 | 11/17/2021 | 06/10/2022 |
| PAR-22-062 | Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 11/03/2021 | 01/07/2025 |
| PAR-22-061 | Modulating Human Microbiome Function to Enhance Immune Responses Against Cancer (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 11/03/2021 | 01/07/2025 |
| RFA-CA-22-004 | Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) | HHS-NIH11 | 11/03/2021 | 09/22/2022 |
| RFA-CA-22-003 | Innovative Biospecimen Science Technologies for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) | HHS-NIH11 | 11/03/2021 | 09/22/2022 |
| PAR-21-329 | Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional) | HHS-NIH11 | 09/22/2021 | 11/05/2024 |
| PAR-21-300 | NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Independent Clinical Trial Not Allowed) | HHS-NIH11 | 09/10/2021 | 09/07/2024 |
| PAR-21-302 | NCI Transition Career Development Award to Promote Diversity (K22 Clinical Trial Required) | HHS-NIH11 | 09/10/2021 | 09/07/2024 |
| PAR-21-299 | NCI Mentored Clinical Scientist Research Career Development Award to Promote Diversity (K08 Clinical Trial Required) | HHS-NIH11 | 09/10/2021 | 09/07/2024 |
| RFA-CA-21-020 | National Cancer Institute Youth Enjoy Science Research Education Program (R25 Clinical Trial Not Allowed) | HHS-NIH11 | 09/01/2021 | 09/28/2023 |
| PAR-21-296 | NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Clinical Trial Required) | HHS-NIH11 | 08/31/2021 | 11/12/2024 |
| PAR-21-295 | NCI Mentored Research Scientist Development Award to Promote Diversity (K01 Independent Clinical Trial Not Allowed) | HHS-NIH11 | 08/31/2021 | 11/12/2024 |
| PAR-21-278 | Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed) | HHS-NIH11 | 08/26/2021 | 09/07/2024 |
| PAR-21-279 | Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed) | HHS-NIH11 | 08/26/2021 | 09/07/2024 |
| PAR-21-294 | Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 07/22/2021 | 09/07/2024 |
| PAR-21-290 | Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional) | HHS-NIH11 | 07/22/2021 | 09/07/2024 |
| PAR-21-138 | Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 Clinical Trial Optional) | HHS-NIH11 | 06/03/2021 | 12/01/2024 |
| PAR-21-138 | Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 Clinical Trial Optional) | HHS-NIH11 | 06/03/2021 | 12/01/2024 |
| PAR-21-061 | Exploratory Grant Award to Promote Workforce Diversity in Basic Cancer Research (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 03/18/2021 | 11/17/2023 |
| PAR-21-128 | The NCI Transition Career Development Award (K22 - Independent Clinical Trial Not Allowed) | HHS-NIH11 | 03/15/2021 | 03/14/2024 |
| PAR-21-318 | The NCI Transition Career Development Award (K22 Independent Basic Experimental Studies with Humans Required) | HHS-NIH11 | 03/15/2021 | 03/14/2024 |
| PAR-21-111 | The NCI Transition Career Development Award (K22 - Independent Clinical Trial Required) | HHS-NIH11 | 03/15/2021 | 03/14/2024 |
| PAR-21-190 | Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) | HHS-NIH11 | 03/12/2021 | 03/07/2024 |
| RFA-OD-21-004 | Maximizing the Scientific Value of Existing Biospecimen Collections (R21 Clinical Trial Not Allowed) | HHS-NIH11 | 03/10/2021 | 03/08/2023 |
| PAR-21-065 | Cancer Research Education Grants Program - Curriculum or Methods Development (R25 Clinical Trial Not Allowed) | HHS-NIH11 | 11/17/2020 | 01/07/2024 |
| PAR-21-066 | Cancer Research Education Grants Program - Courses for Skills Development (R25 Clinical Trial Not Allowed) | HHS-NIH11 | 11/17/2020 | 01/07/2024 |
| PAR-21-067 | Cancer Research Education Grants Program - Research Experiences (R25 Clinical Trial Not Allowed) | HHS-NIH11 | 11/17/2020 | 01/07/2024 |
| PAR-21-033 | National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) | HHS-NIH11 | 11/12/2020 | 01/07/2024 |
| PAR-21-035 | Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) | HHS-NIH11 | 11/10/2020 | 01/07/2024 |
| PAR-20-305 | Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2021, 2022, and 2023 (P50 Clinical Trial Required) | HHS-NIH11 | 09/28/2020 | 01/07/2024 |
| PAR-20-303 | Tobacco Control Policies to Promote Health Equity (R21 Clinical Trial Optional) | HHS-NIH11 | 09/04/2020 | 09/07/2023 |
| PAR-20-302 | Tobacco Control Policies to Promote Health Equity (R01 Clinical Trial Optional) | HHS-NIH11 | 09/04/2020 | 09/07/2023 |
| PAR-20-292 | NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) | HHS-NIH11 | 08/24/2020 | 07/20/2022 |
| PAR-20-284 | Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed) | HHS-NIH11 | 08/13/2020 | 05/04/2023 |
|
Fertility Status as a Marker for Overall Health (R21 Clinical Trial Not Allowed) |
HHS-NIH11 |
07/23/2020 |
06/19/2023 |
|
|
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed) |
HHS-NIH11 |
07/22/2020 |
09/07/2022 |
|
|
Secondary Analysis and Integration of Existing Data to Elucidate the Genetic Architecture of Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed) |
HHS-NIH11 |
07/22/2020 |
09/07/2022 |
|
|
NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required) |
NIH |
05/20/2020 |
05/07/2023 |
|
|
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional) |
NIH |
03/30/2020 |
09/07/2022 |
|
|
Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed) |
NIH |
03/12/2020 |
05/07/2023 |
|
|
National Cancer Institute Program Project Applications (P01 Clinical Trial Optional) |
NIH |
01/27/2020 |
05/07/2023 |
|
|
Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed) |
NIH |
12/10/2019 |
10/28/2022 |
|
|
Co-infection and Cancer (R21 Clinical Trial Not Allowed) |
NIH |
11/22/2019 |
01/07/2023 |
|
|
Co-infection and Cancer (R01 Clinical Trial Not Allowed) |
NIH |
11/22/2019 |
01/07/2023 |
|
|
Program to Assess the Rigor and Reproducibility of Extracellular Vesicle-Derived Analytes for Cancer Detection (R01 Clinical Trial Not Allowed) |
NIH |
11/12/2019 |
01/07/2023 |
|
|
NCI Small Grants Program for Cancer Research for Years 2020, 2021, and 2022 (NCI Omnibus R03 Clinical Trial Optional) |
NIH |
11/08/2019 |
01/07/2023 |
|
|
Perception and Cognition Research to Inform Cancer Image Interpretation (R21 Clinical Trial Optional) |
NIH |
10/02/2019 |
01/07/2023 |
|
|
Perception and Cognition Research to Inform Cancer Image Interpretation (R01 Clinical Trial Optional) |
NIH |
10/02/2019 |
01/07/2023 |
|
|
Small Research Grants for Analyses of Gabriella Miller Kids First Pediatric Research Data (R03 Clinical Trial Not Allowed) |
NIH |
09/12/2019 |
01/07/2023 |
|
|
Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R01 Clinical Trial Optional) |
NIH |
08/29/2019 |
09/07/2022 |
|
|
Intervening with Cancer Caregivers to Improve Patient Health Outcomes and Optimize Health Care Utilization (R21 Clinical Trial Optional) |
NIH |
08/29/2019 |
09/07/2022 |
|
|
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R01 Clinical Trial Optional) |
NIH |
08/29/2019 |
09/07/2022 |
|
|
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R03 Clinical Trial Optional) |
NIH |
08/29/2019 |
07/16/2022 |
|
|
Linking the Provider Recommendation to Adolescent HPV Vaccine Uptake (R21 Clinical Trial Optional) |
NIH |
08/29/2019 |
09/07/2022 |
|
|
NCI Clinical and Translational Exploratory/Developmental Studies (R21 Clinical Trial Optional) |
NIH |
08/28/2019 |
07/20/2022 |
|
|
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R01 Clinical Trial Optional) |
NIH |
08/16/2019 |
06/08/2022 |
|
|
Innovative Approaches to Studying Cancer Communication in the New Information Ecosystem (R21 Clinical Trial Optional) |
NIH |
08/16/2019 |
06/08/2022 | |
| PAR-19-339 | Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R21 Clinical Trial Optional) | NIH | 08/12/2019 | 06/08/2022 |
| PAR-19-340 | Leveraging Cognitive Neuroscience to Improve Assessment of Cancer Treatment-Related Cognitive Impairment (R01 Clinical Trial Optional) | NIH | 08/12/2019 | 06/08/2022 |
|
Stimulating Innovations in Behavioral Intervention Research for Cancer Prevention and Control (R21 Clinical Trial Optional) |
NIH |
06/28/2019 |
09/07/2022 |